Biotechnology company Vyriad has revealed plans to construct a facility in Rochester, Minnesota, to manufacture its oncolytic virus therapies for the treatment of various cancers.

The company has signed a contract for the construction of the 25,000 square foot production facility on the IBM Campus.

The new plant will have offices, research laboratories, and an advanced Good Manufacturing Practice (GMP) facility. It will facilitate production, quality-control testing, and the delivery of clinical-grade oncolytic virus therapies for later-stage clinical studies.

Around $370,000 in equipment funding will be provided by the state of Minnesota and the city of Rochester. In addition, proceeds from $9m secured convertible note financing will be used to fund the construction of the facility.

“With two clinical-stage oncolytic virotherapy platforms and an expanding pre-IND pipeline, this Rochester facility will enable us to more rapidly advance our multi-pronged assault on cancer.”

Mayo Clinic, Rochester Area Economic Development, and the Southeast Minnesota Capital Fund participated in the convertible note financing.

Vyriad President and CEO Dr Stephen Russell said: “With the custom buildout of this facility, Vyriad is taking a giant leap forward in delivering our novel oncolytic virus therapies to patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“With two clinical-stage oncolytic virotherapy platforms and an expanding pre-IND pipeline, this Rochester facility will enable us to more rapidly advance our multi-pronged assault on cancer. We greatly appreciate the strong support we have received from Mayo Clinic and at the local and state levels, and we look forward to continuing to work with Mayo Clinic in our mission to deliver important new therapies to patients as well as drive local bioinnovation and economic development in Rochester and Minnesota for years to come.”

The initial buildout of the new plant has already started and the facility will be fully operational in the fourth quarter of this year.

Following its completion, Vyriad’s employees will work together from one location at the facility.